Correction to: Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK2140944)

From BugSigDB
incomplete
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI Uniform resource identifier for web resources.
Authors
Nuzzo A, Van Horn S, Traini C, Perry CR, Dumont EF, Scangarella-Oman NE, Gardiner DF, Brown JR
Journal
BMC microbiology
Year
2021

Experiment 1


incomplete

Curated date: 2021/11/01

Curator: Gina

Revision editor(s): LGeistlinger, Gina

Subjects

Location of subjects
United States of America
Host species Species from which microbiome was sampled (if applicable)
Homo sapiens


Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
two or more of the following clinical signs and symptoms with onset ≤72 h at screening: dysuria, frequency, urgency, or lower abdominal pain They were required to have pyuria (≥10 white blood cells/mm3 or the presence of leukocyte esterase) and/or nitrite from a pretreatment urine sample.
Group 0 sample size Number of subjects in the control (unexposed) group
22
Group 1 sample size Number of subjects in the case (exposed) group
22
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
Participants who had any preexisting condition that may have impacted gepotidacin absorption, distribution, metabolism, or excretion were excluded.